Get started
Author

David L. Bourdet

Observed names: Bourdet, David, D Bourdet, D L Bourdet, D. Bourdet, D.L. Bourdet, DAVID BOURDET, David Bourdet, David L Bourdet
ORCID: 0000-0001-6220-1922
Observed ORCID: 0000-0001-6220-1922
OpenAlex ID: A5027600676
Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence-Based Position
2013 · J C Kalvass, J W Polli, et al. · Clinical Pharmacology & Therapeutics · 205
Mechanisms Underlying Saturable Intestinal Absorption of Metformin
2008 · William R. Proctor, David L. Bourdet, et al. · Drug Metabolism and Disposition · 133
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective
2018 · J. Gerry Kenna, Kunal S. Taskar, et al. · Clinical Pharmacology & Therapeutics · 127
PDF
Differential Substrate and Inhibitory Activities of Ranitidine and Famotidine toward Human Organic Cation Transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3)
2005 · David L. Bourdet, John B. Pritchard, et al. · Journal of Pharmacology and Experimental Therapeutics · 109
Ritonavir, Saquinavir, and Efavirenz, but Not Nevirapine, Inhibit Bile Acid Transport in Human and Rat Hepatocytes
2006 · Mary Peace McRae, Carolina M. Lowe, et al. · Journal of Pharmacology and Experimental Therapeutics · 100
Biotransformation and bioactivation reactions of alicyclic amines in drug molecules
2014 · Jayaprakasam Bolleddula, Kevin DeMent, et al. · Drug Metabolism Reviews · 86
5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment
2011 · Fei Shen, Jacqueline A.M. Smith, et al. · Neuropharmacology · 83
Intestinal Absorptive Transport of the Hydrophilic Cation Ranitidine: A Kinetic Modeling Approach to Elucidate the Role of Uptake and Efflux Transporters and Paracellular vs. Transcellular Transport in Caco-2 Cells
2006 · David L. Bourdet, Gary M. Pollack, et al. · Pharmaceutical Research · 58
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
2021 · Dave Singh, Maxim Bogus, et al. · European Respiratory Journal · 46
PDF
Next‐Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development
2019 · Sharin E. Roth, Mark I. Avigan, et al. · Clinical Pharmacology & Therapeutics · 45
PDF
Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies
2017 · Dean Quinn, Christopher N. Barnes, et al. · Pulmonary Pharmacology & Therapeutics · 40
PDF
Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B
2013 · Ryan C. Schoenfeld, David L. Bourdet, et al. · Journal of Medicinal Chemistry · 39
Saturable Absorptive Transport of the Hydrophilic Organic Cation Ranitidine in Caco-2 Cells: Role of pH-Dependent Organic Cation Uptake System and P-Glycoprotein
2006 · David L. Bourdet, Dhiren R. Thakker · Pharmaceutical Research · 38
Effect of Hepatitis C Virus Infection on the mRNA Expression of Drug Transporters and Cytochrome P450 Enzymes in Chimeric Mice with Humanized Liver
2010 · Ryota Kikuchi, Matthew McCown, et al. · Drug Metabolism and Disposition · 35
Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
2021 · Juliana Hey-Hadavi, Daniel Seekins, et al. · Drug Safety · 31
Why Does the Intestine Lack Basolateral Efflux Transporters for Cationic Compounds? A Provocative Hypothesis
2016 · William R. Proctor, Xin Ming, et al. · Journal of Pharmaceutical Sciences · 31
Novel Series of Dihydropyridinone P2X7 Receptor Antagonists
2015 · Francisco Lopez-Tapia, Keith A. M. Walker, et al. · Journal of Medicinal Chemistry · 29
Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species
2022 · Rhiannon N Hardwick, Patrick Brassil, et al. · Toxicological Sciences · 16
Prediction of Human Serotonin and Norepinephrine Transporter Occupancy of Duloxetine by Pharmacokinetic/Pharmacodynamic Modeling in the Rat
2012 · David L. Bourdet, Pamela R. Tsuruda, et al. · Journal of Pharmacology and Experimental Therapeutics · 16
Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19
2021 · Nathan D. Pfeifer, Arthur Lo, et al. · Clinical and Translational Science · 14
PDF
Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials
2019 · James F. Donohue, Gregory Feldman, et al. · Pulmonary Pharmacology & Therapeutics · 14
PDF
Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension
2021 · Arthur Lo, Lucy Norcliffe-Kaufmann, et al. · Clinical Autonomic Research · 12
PDF
Duration by Design: Discovery of Revefenacin, the First-in-Class Nebulized Once-Daily Bronchodilator for the Treatment of Patients With COPD
2016 · Yuhua Ji, Craig Husfeld, et al. · CHEST Journal · 11
PDF
Hepatic Dysfunction Quantified by HepQuant DuO Outperforms Child‐Pugh Classification in Predicting the Pharmacokinetics of Ampreloxetine
2024 · Jitendra Kanodia, Hugh Giovinazzo, et al. · Clinical Pharmacology & Therapeutics · 10
PDF
Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial
2023 · John Belperio, Tuan Nguyen, et al. · BMJ Open Respiratory Research · 10
PDF
Works count: 51
Citation count: 1,401
H-index: 17
I10-index: 26
Year
Topic
Type